Lilly To Rival Pfizer's Ibrance As Early As 2017
This article was originally published in Scrip
Executive Summary
Could Eli Lilly & Co.'s CDK 4/6 inhibitor abemaciclib beat Novartis AG's offering to market and trespass on Pfizer Inc.'s Ibrance (palbociclib) sales more than a year earlier than anticipated?
You may also be interested in...
Lilly’s Abemaciclib Efficacy Data At ASCO Could Hold Up To Accelerated Review
Data presented by Eli Lilly at ASCO could support accelerated approval of abemaciclib but a tolerability issue could impact its competitive position in the commercial market versus Pfizer’s Ibrance.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.